Fundraising FoxForesite Capital — 2018 Investments
6 investments dated 2018 · listed companies and verified rows first · show all
Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.
BiotechCambridge, US
Robert Gould(Executive Officer, Director)inAlex C. Sapir(President and Chief Executive Officer, Director)in
BoardAlan Ezekowitz(Director)inMark Levin(Director)inJames Geraghty(Director)James Collins(Director)
Board seatJames Tananbaum· per SEC Form D
Co-investorsSanofi VenturesThird Rock Ventures
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founders)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsAvoro Capital AdvisorsTPGVida VenturesGilead Sciences
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder)inJ. Keith Joung(Founder)inFeng Zhang(Founder)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesF-Prime CapitalGV (Google Ventures)HongShan Capital Group+2 more
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inCarl Gordon(Director)in
Board seatMichael Rome· per SEC Form D
Co-investorsLongitude CapitalNextech InvestNexTech VenturesOmega FundsOrbiMedPontifax Venture Capital+2 more
A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.
BiotechDigital HealthHealthtechSan Francisco, US
NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)
Co-investorsAisling CapitalRA CapitalViking GlobalViking Global Investors
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsAtlas VentureWellington ManagementCasdin CapitalDeerfield Management CompanyF-Prime CapitalFidelity Investments+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.